IONS — Ionis Pharmaceuticals Cashflow Statement
0.000.00%
- $11.73bn
- $11.38bn
- $943.71m
Annual cashflow statement for Ionis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.6 | -270 | -366 | -454 | -381 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 155 | -29 | 123 | 150 | 152 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -114 | 7.57 | -77.3 | -209 | -51.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 30.8 | -274 | -308 | -501 | -269 |
| Capital Expenditures | -12 | -15.7 | -23.8 | -45.3 | -51.4 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 207 | -247 | -190 | -88.7 | -226 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Cash from Investing Activities | 195 | -263 | -214 | -134 | -278 |
| Financing Cash Flow Items | -169 | -11 | 7.74 | 0 | -18.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 246 | -55.3 | 644 | 478 | 676 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 472 | -593 | 123 | -157 | 130 |